Rinsho Shinkeigaku (Clinical Neurology)

The 49th Annual Meeting of the Japanese Society of Neurology

Neuroprotective therapy for ischemic stroke with free radical scavenger and gene-stem cell therapy

Koji Abe, M.D., Ph.D.

Department of Neurology, Graduate School of Medicine and Dentistry, Okayama University

A free radical scavenger Edaravone is the first clinical drug for neuroprotection in the world which has been used from 2001 in most ischemic stroke patients in Japan, and is especially useful in thrombolytic therapy with tissue plasminogen activator (tPA). Of great importance for regenerative therapy and gene therapy are the neural stem cells which are intrinsically activated or exogenously transplanted. Addition of NTFs greatly enhanced an intrinsic migration or invasion of stem cells into the scaffold, which could provide a future regenerative potential against ischemic brain damage at chronic stage.
Full Text of this Article in Japanese PDF (410K)

(CLINICA NEUROL, 48: 896|898, 2008)
key words: Cerebral infarction, neuroprotection, edaravone, gene therapy, restorative therapy

(Received: 16-May-08)